Daniel A. Morgenstern

4.1k total citations
89 papers, 2.6k citations indexed

About

Daniel A. Morgenstern is a scholar working on Neurology, Oncology and Molecular Biology. According to data from OpenAlex, Daniel A. Morgenstern has authored 89 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Neurology, 31 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Daniel A. Morgenstern's work include Neuroblastoma Research and Treatments (46 papers), Cancer, Hypoxia, and Metabolism (15 papers) and Neuroendocrine Tumor Research Advances (10 papers). Daniel A. Morgenstern is often cited by papers focused on Neuroblastoma Research and Treatments (46 papers), Cancer, Hypoxia, and Metabolism (15 papers) and Neuroendocrine Tumor Research Advances (10 papers). Daniel A. Morgenstern collaborates with scholars based in Canada, United States and United Kingdom. Daniel A. Morgenstern's co-authors include James W. Fawcett, Richard Asher, Kathryn H. Adcock, Joel M. Levine, John Rogers, John Anderson, Meredith S. Irwin, Richard U. Margolis, Atsuhiko Oohira and Lawrence Moon and has published in prestigious journals such as Nature Communications, Neuron and Journal of Clinical Oncology.

In The Last Decade

Daniel A. Morgenstern

79 papers receiving 2.5k citations

Peers

Countries citing papers authored by Daniel A. Morgenstern

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Morgenstern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Morgenstern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Morgenstern more than expected).

Fields of papers citing papers by Daniel A. Morgenstern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Morgenstern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Morgenstern. The network helps show where Daniel A. Morgenstern may publish in the future.

Co-authorship network of co-authors of Daniel A. Morgenstern

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Morgenstern. A scholar is included among the top collaborators of Daniel A. Morgenstern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Morgenstern. Daniel A. Morgenstern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma. 2024 ·Journal of Clinical Oncology ·Jaume Mora, Godfrey Chi Fung Chan, Daniel A. Morgenstern, Loredana Amoroso, Karsten Nysom, Joerg Faber, Arthur Wingerter, (unknown), (unknown), James Eldridge, Karen Tornøe, Maria Düring, Brian H. Kushner	2
2	Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121. 2024 ·Journal of Clinical Oncology ·Daniel A. Morgenstern, Michela Casanova, Cornelis M. van Tilburg, David S. Ziegler, (unknown), Tanya Watt, Alberto S. Pappo, Theodore W. Laetsch, (unknown), (unknown), (unknown), Jennifer Wright, Hyoung Jin Kang	2
3	Characterisation of Paediatric Neuroblastic Tumours by Quantitative Structural and Diffusion-Weighted MRI 2024 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), Rahim Moineddin, Shelley A. Harris, Anita Villani, David Malkin, Daniel A. Morgenstern, Andréa S. Doria	0
4	How we approach early phase clinical trial and off-label therapy consults in pediatric oncology: The New Agents and Innovative Therapy (NAIT) team experience 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Karen Fung, (unknown), Daniel A. Morgenstern, Sarah Cohen‐Gogo	0
5	Synchronous T-lymphoblastic lymphoma and neuroblastoma in a 3-yr-old with novel germlineSMARCA4andEZH2variants 2023 ·Molecular Case Studies ·(unknown), (unknown), Nisha Kanwar, Kyoko E. Yuki, Adam Shlien, Bo Ngan, Meredith S. Irwin, Daniel A. Morgenstern, Johann Hitzler, Anita Villani, Sarah Cohen‐Gogo	1
6	783 Combined immunotherapy improves outcome for replication repair deficient (RRD) high-grade glioma failing anti-PD1 monotherapy: a report from the International RRD consortium 2023 ·SHILAP Revista de lepidopterología ·Anirban Das, (unknown), Adrian Levine, Vanessa Bianchi, (unknown), Melissa Edwards, Trevor J. Pugh, Derek S. Tsang, Birgit Ertl‐Wagner, Daniel A. Morgenstern, Cynthia Hawkins, Éric Bouffet, Uri Tabori	0
7	129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score 2023 ·Immuno-Oncology Technology ·Brian H. Kushner, Jaume Mora, Gcf Chan, Daniel A. Morgenstern, Loredana Amoroso, (unknown), Joerg Faber, Arthur Wingerter, (unknown), (unknown), (unknown), Karen Tornøe	1
8	Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus 2023 ·Pediatric Blood & Cancer ·Karsten Nysom, (unknown), (unknown), (unknown), Araz Marachelian, Tanya Watt, Daniel A. Morgenstern	5
9	Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study 2022 ·JCO Precision Oncology ·(unknown), Anirban Das, Daniel A. Morgenstern, Sumedha Sudhaman, Vanessa Bianchi, (unknown), (unknown), Melissa Edwards, David E. Kram, Michael Osborn, Cynthia Hawkins, Éric Bouffet, Yoon‐Jae Cho, Uri Tabori	9
10	963MO Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201 2021 ·Annals of Oncology ·Jaume Mora, Misty D. Bear, Gcf Chan, Daniel A. Morgenstern, Karsten Nysom, Karen Tornøe, Nedjad Losic, Brian H. Kushner	4
11	MYOCARDITIS RESPONSE TO COLCHICINE THERAPY BASED ON CARDIAC MRI DIAGNOSTIC CRITERIA 2021 ·Journal of the American College of Cardiology ·(unknown), (unknown), Daniel A. Morgenstern, J. Ronald Mikolich	5
12	443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082) 2020 ·Annals of Oncology ·Nathalie Gaspar, Quentin Campbell‐Hewson, Stefan Bielack, (unknown), Francisco Bautista, Cristina Meazza, Katherine A. Janeway, Filemon S. Dela Cruz, Sarah Burkhead Whittle, Daniel A. Morgenstern, Lea Dutta, Jodi A. McKenzie, (unknown), (unknown), Chinyere E. Okpara, (unknown), (unknown), (unknown)	0
13	1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082) 2020 ·Annals of Oncology ·Nathalie Gaspar, Quentin Campbell‐Hewson, Stefan Bielack, (unknown), Francisco Bautista, Cristina Meazza, Katherine A. Janeway, Filemon S. Dela Cruz, Sarah Burkhead Whittle, Daniel A. Morgenstern, Lea Dutta, Jodi A. McKenzie, (unknown), Jie Huang, Chinyere E. Okpara, Behzad Bidadi, (unknown), (unknown)	2
14	Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies 2018 ·Future Oncology ·Andrew E. Place, Kelly C. Goldsmith, Jean‐Pierre Bourquin, Mignon L. Loh, Lia Gore, Daniel A. Morgenstern, Yeshwant D. Sanzgiri, David Hoffman, Ying Zhou, Jeremy A. Ross, Betty Prine, Mohamad Shebley, (unknown), Thalia A. Farazi, Su Young Kim, Maria Verdugo, (unknown), C. Michel Zwaan, Josef Vormoor	39
15	Post‐thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes 2016 ·British Journal of Haematology ·Daniel A. Morgenstern, Gulrukh Ahsan, (unknown), Stuart J. Ings, (unknown), Paul Veys, Penelope Brock, John Anderson, Persis Amrolia, Nicholas Goulden, Catherine M. Cale, Michael Watts	32
16	OUT-PATIENT CHEST PAIN: ECONOMIC IMPACT OF INITIAL DIAGNOSTIC TESTING CHOICE 2016 ·Journal of the American College of Cardiology ·(unknown), (unknown), (unknown), Daniel A. Morgenstern, John Lisko, J. Ronald Mikolich	0
17	The immune response in paediatric cancer 2010 ·UCL Discovery (University College London) ·Daniel A. Morgenstern, John Anderson	2
18	Migratory and Antigen Presentation Functions of IFN-Producing Killer Dendritic Cells 2009 ·Cancer Research ·Nourredine Himoudi, Mengyong Yan, Gerben Bouma, Daniel A. Morgenstern, Rebecca Wallace, (unknown), (unknown), Ayad Eddaoudi, (unknown), Nichola Cooper, John Anderson	11
19	Clinical and pathological features of paediatric malignant rhabdoid tumours 2009 ·Pediatric Blood & Cancer ·Daniel A. Morgenstern, Sian Gibson, (unknown), Neil J. Sebire, John Anderson	55
20	Chapter 22 Chondroitin sulphate proteoglycans in the CNS injury response 2002 ·Progress in brain research ·Daniel A. Morgenstern, Richard Asher, James W. Fawcett	345

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact